Despite Pfizer's (NYSE: PFE) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

Plans to build 112 homes on land once occupied by Pfizer have been granted - but none of the properties will be classed as ...

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Provera, Kelly Wright says she began experiencing "alarming" symptoms, including severe migraines and vision impairment.

Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...

The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...

No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...